Barry I Hudson1, Chuanhui Dong2, Hannah Gardener3, Mitchell S V Elkind4, Clinton B Wright5, Ron Goldberg6, Ralph L Sacco7, Tatjana Rundek7. 1. Division of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address: bhudson@med.miami.edu. 2. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 3. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 4. Stroke Division, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman Public School of Health, Columbia University, New York, NY, USA. 5. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Neuroscience Program, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 6. Division of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA. 7. Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Abstract
OBJECTIVE: Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. MATERIALS/ METHODS: From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. RESULTS: The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p<0.0001), blood pressure (p=0.0014), and fasting glucose (p<0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. CONCLUSIONS: sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.
OBJECTIVE: Recent studies have shown a strong link between serum soluble receptor for advanced glycation end-products (sRAGE) levels and cardiovascular risk factors and disease. What is less clear is the relationship between metabolic risk factors and sRAGE levels. Here, we tested the hypothesis that lower sRAGE levels may be associated with the metabolic syndrome (MetS) in an urban multi ethnic population. MATERIALS/ METHODS: From the Northern Manhattan Study (NOMAS), we included 1101 stroke-free participants (mean age: 71 ± 9 years, 60% women, 64% Hispanic, 18% black, 16% white). Serum sRAGE was measured by ELISA. Quantile regression analysis was performed to evaluate the association between sRAGE and MetS components and MetS, after adjusting for sociodemographics, smoking status and kidney function. RESULTS: The median (interquartile) sRAGE was 899 pg/ml (647-1248 pg/ml), 42% had metabolic syndrome. The prevalence of unfavorable metabolic factors was 50% for waist circumference (WC), 81% for blood pressure, 39% for fasting glucose, 35% for reduced high density lipoproteins (HDL), and 23% for triglycerides. After adjustment, the median sRAGE levels were at least 120 pg/ml lower in those who had elevated WC (p<0.0001), blood pressure (p=0.0014), and fasting glucose (p<0.0001), and those who had 2 or more unfavorable metabolic factors. No relationship was seen between sRAGE levels and elevated triglycerides or reduced HDL levels. Interaction and stratified analyses revealed that the association of sRAGE with MetS was more prominent in Hispanics compared to whites, and displaying no association with components of MetS in blacks. CONCLUSIONS: sRAGE levels were mainly associated with MetS factors related to obesity, diabetes and hypertension, and displayed variation with ethnicity in a multi-ethnic population. Further studies of sRAGE, MetS and their relationship to cardiovascular disease are warranted.
Authors: Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind Journal: Atherosclerosis Date: 2011-01-21 Impact factor: 5.162
Authors: Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer Journal: Diabetes Date: 2010-06-03 Impact factor: 9.461
Authors: Bernadette Boden-Albala; Ralph L Sacco; Hye-Sueng Lee; Cairistine Grahame-Clarke; Tanja Rundek; Mitchell V Elkind; Clinton Wright; Elsa-Grace V Giardina; Marco R DiTullio; Shunichi Homma; Myunghee C Paik Journal: Stroke Date: 2007-12-06 Impact factor: 7.914
Authors: Helen M Colhoun; D John Betteridge; Paul Durrington; Graham Hitman; Andrew Neil; Shona Livingstone; Valentine Charlton-Menys; Weihang Bao; David A Demicco; Gregory M Preston; Harshal Deshmukh; Kathryn Tan; John H Fuller Journal: Diabetes Date: 2011-07-19 Impact factor: 9.461
Authors: Jason B Lindsey; James A de Lemos; Francesco Cipollone; Colby R Ayers; Anand Rohatgi; David A Morrow; Amit Khera; Darren K McGuire Journal: Diabetes Care Date: 2009-04-14 Impact factor: 19.112
Authors: Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley Journal: Metabolism Date: 2017-02-10 Impact factor: 8.694
Authors: Barry I Hudson; Hannah Gardener; Wen Liu-Mares; Chuanhui Dong; Ken Cheung; Mitchell S V Elkind; Clinton B Wright; Ralph L Sacco; Tatjana Rundek Journal: Atherosclerosis Date: 2015-02-24 Impact factor: 5.162